Compare CMTL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | MAIA |
|---|---|---|
| Founded | 1967 | 2018 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 89.7M |
| IPO Year | 2024 | 2022 |
| Metric | CMTL | MAIA |
|---|---|---|
| Price | $4.85 | $1.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 224.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $0.87 |
| 52 Week High | $6.21 | $3.19 |
| Indicator | CMTL | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 38.16 |
| Support Level | $2.74 | $1.44 |
| Resistance Level | $6.15 | $1.52 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 18.30 | 12.86 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.